INJECTABLE METHOTREXATE
Methotrexate is an anti-neoplastic or chemotherapeutic agent used primarily in the
treatment of cancer. Methotrexate has immunosuppressive properties and is often used to treat a number on non-cancer related disorders. It is important to note that regardless of the indication for Methotrexate, it is still considered to be a
chemotherapeutic agent, and must be regarded as such. Basic pharmacology and medication administration courses offered in or post graduate
LPN programs have little chemotherapy content. The resulting lack of chemotherapy education means that administration of this drug, in its injectable form, is considered to be beyond the entry level practice of the LPN. LPNs with the necessary competency (knowledge, skill and judgment) may administer oral Methotrexate or other oral chemotherapy. Can LPNs administer Methotrexate by injection? In appropriate contexts, LPNs may administer Methotrexate by injection* to clients who
have established care plans, and where (as a part of the plan of care), the patient’s
response to the Methotrexate is both known and reasonably anticipated. LPNs may engage in this skill following the completion of an employer based Formal Shared Competency. The purpose of the formal shared competency is to provide the practical
nurse with the necessary education and background information so they can competently administer and care for patients receiving Methotrexate. All nurses are accountable for safe and competent medication administration. Safe administration of
this medication will require knowledge of pertinent drug and client information including action, duration, dose, frequency, purpose, side effects, and all nursing implications. LPNs are expected to follow a medication protocol regarding the proper client assessment, medication administration, handling, storage or disposal as outlined
in an agency policy. Competence (via the formal shared competency process) must be achieved and documented before administration of this medication. * Subcutaneous or intramuscular ONLY. IV administration of Methotrexate (intermittent or IV push) is beyond the scope of practice of the LPN and is not subject to a formal shared competency at this time (See LPNs and Administration of IV Medications). Can LPNs administer injectable Methotrexate? Page 1 I was planning to go to a client’s home to have someone show me how to administer Methotrexate and “sign me off”. Would this be enough to satisfy a formal shared competency? No. Shared Competencies are advanced skills gained through additional and specialty education or clinical practice. LPNs have the necessary general or
background education and knowledge to support learning a shared competency, but not the specific education and knowledge to enact the competency. A Formal Shared Competency, such as the administration of Methotrexate, is a new technical skill built
on advanced (or new) PN knowledge and education. Formal shared competencies require a structured educational program/session made up of a: 1. Learning module
2. Clinical learning opportunity and 3. Policy to support the LPN to enact the competency. A policy outlines the process
of achieving, maintaining and documenting the competency.
Formal shared competencies represent a specific practice, and as such require ongoing or regular (annually, for example) recertification beyond the initial competency process.
It is not the responsibility of CLPNNS to create these programs. The nurse and the employer share the accountability to develop, implement, sustain and document this program and process.
LPNs are not be permitted to administer Methotrexate until all three components of the
formal shared competency are successfully completed or in place. It is particularly important for nurses and employers to understand that work-place policy, which permit
the LPN to engage in the skill and outlines the processes in place to support achieving competency, must be official and approved by the organization. Polices in “draft” or “under development” are not sufficient to support the advanced practice of the LPN.
Successfully completing the required elements of a shared competency permits the LPN to add that particular skill to their practice, in appropriate contexts. Shared
competencies are not transferable and apply to one practice setting at a time. This
means that an LPN competent to perform a skill in one clinical area may not be supported to perform it in another. For example, an LPN has become competent and is supported by policy to administer Methotrexate in an outpatient clinic may be limited in
administering Methotrexate in a home care setting, if there is no policy supporting the practice in the home care context. I work in a pharmacy with a registered pharmacist. I have been asked to mix and prepare Methotrexate. Is this within my scope of practice? LPNs can work in a variety of practice settings, including the pharmacy. In this practice
context, (the pharmacy) the LPN works in collaboration with or under the guidance/
Can LPNs administer injectable Methotrexate? Page 2
direction of the pharmacist. LPNs have basic pharmacology and medication administration knowledge. In the clinical setting, this knowledge is used to perform the
necessary patient assessments before, during and after the administration of medications. Mixing or preparing Methotrexate, or any chemotherapy (regardless of their use) is not a part of the basic pharmacology and medication administration course
(in-program or post-graduate) and therefore, like the administration of Methotrexate, is
considered to be a beyond entry level competency for LPNs. If a nurse and employer wish to have an LPN mix and prepare Methotrexate, a formal shared competency process (learning module specific to the preparation of Methotrexate, clinical learning
opportunity to demonstrate technical competence and an official policy supporting LPN practice in this tasks) is required. Please Note: It is important to recognize the practice differences between medication administration and medication mixing/preparing in the pharmacy context. A shared competency focused only on the practice of administering Methotrexate, will not satisfy the competency requirements for the practice of mixing or preparing Methotrexate. The
learning module of the shared competency must be specific to all the practices it is to support. Could I or my employer be asked to provide the content of a shared competency to CLPNNS? Typically no. CLPNNS provides counsel and guidance to nurses and employers as requested but generally does not review, approve or deny the content of any employer based shared competency. This said, nurses and employers hold the accountability of providing shared competency content if required. (See Guide to Continuing Competence
Program) References
College of Licensed Practical Nurses of Alberta. (2011). Ask a Practice Consultant: Can LPNs Administer Methotrexate? Care: Exploring the Emotional and Practical realities of Healthcare. 25(1), 34. College of Licensed Practical Nurses of Nova Scotia, (2009). Administrative Policy: Request for Shared Competencies, Halifax, Author. College of Licensed Practical Nurses of Nova Scotia, (2011). ELC and SC: Practice Update: March 2011, Halifax, Author. College of Licensed Practical Nurses of Nova Scotia. (2011) Practice Guidelines: LPNs
and Administration of IV Medications. Halifax: Author.
Wilson, B,. Shannon, M., Stang, C. (Eds.). (2002). Nurses Drug Guide. Upper Saddle
Can LPNs administer injectable Methotrexate? Page 3
(Sº de Salud Laboral del SOMA-FIA-UGT) La globalización económica y las nuevas tecnologías de la información son, como reconoce la Comisión Europea en su Documento de consulta sobre desarrollo sostenible, importantes estímulos para incrementar la eficiencia y la productividad y ofrecen nuevas oportunidades de Pero estos cambios tan positivos –añade- no deben impedirnos ver s
Product Information www.neuroeffex.com NutriNerve® 2007 ADA Scientific Session – Oral Presentation Soft Gels Effect of 4-Year Antioxidant Treatment with Alpha-Lipoic Acid in Diabetic What is in NutriNerve® 2.2? A patented formulation that supports the body against neuropathy* Results : The aim of this study was to evaluate the efficacy and safety of [alpha]-l